Safe effective triple therapy of infantile hemangioma using oral Propranolol and oral prednisolone plus topical timolol drops in series of 182 infants.
Keywords:
Infantile hemangioma, Propranolol, Prednisolone, Timolol, Laser therapy, Triple therapyAbstract
Background Infantile hemangioma is a common vascular tumor that involute gradually as part of natural course but in many cases it needs active treatment especially when they are located adjacent to a vital organ or huge in size by using oral propranolol or other alternative measure. Objective To record personal experience in treating infantile hemangioma using triple therapy on home basis. Patients and Methods This is a case series cross sectional clinical study and therapeutic trial of infantile hemangioma(IH) was carried out during the period from 2014-2022 where all cases with infantile hemangioma were evaluated. All types of hemangioma were included single or multiple superficial and deep. Oral propranolol was given at home in a dose of 1-2 mg/kg body weight a day in two divided doses. Oral prednisolone was started as 5mg syrup once a day for one month and then tapered gradually. Also timolol drop 0.5% was applied to hemangioma twice a day till the end of therapy. The duration of treatment ranged from 3-6 months with a median of 4 months. Objective scoring was used to assess the response to therapy. All side effects were carefully recorded by the mothers and dermatologist. Results A total of 182 infants,129(70.87%) females and 53 (29.12%) males with IHs were included and analyzed. The age of the patients ranged from 1-6 months with a mean of 4 months. The sites of lesions were mostly on heads including face and neck in 106(58.24%) cases while in other parts of body in 76(41.75%) cases, with size ranged from 2 cm2 to 23 cm2. The response to triple therapy was noticed week after starting treatment protocol but was obvious at 2 weeks. There was gradual reduction in color and size of lesions. In most of patients, there was about 25% reduction in the first two weeks that reached to 75-100% after 3-6 months. No adverse or side effects were seen in all infants even with normal growth development. Conclusion This triple therapy is the first study using oral propranolol and oral prednisolone plus topical timolol drops together on a home basis. It is safe effective therapy for infantile hemangioma and is more effective than single drug use. No need for hospital admission or cardiac assessment during treatment course and no laser therapy is recommended.References
References
Aizman L, Van Den Anker J, Tender J, et al. Special management considerations for
propranolol use in breastfed infants of mothers taking antihypertensives. Pediatr Dermatol.2020 ;37:537–540.
Munden A, Butschek R, Tom WL, et al. Prospective study of infantile haemangiomas:
Incidence, clinical characteristics and association with placental anomalies. Br J Dermatol. 2014; 170:907–913.
Maguiness SM. Vascular tumors and malformations in children, Introduction. Semin Cutan Med Surg. 2016 ;35(3):107.
Greenberger S, Bischoff J. Pathogenesis of infantile haeman- gioma. Br J Dermatol. 2013;169(1): 12–9.
Itinteang T, Withers AH, Davis PF, Tan ST. Biology of infantile hemangioma. Front Surg.2014; 1: 38.
Boscolo E, Bischoff J. Vasculogenesis in infantile hemangioma. Angiogenesis. 2009; 12(2):197–207.
Marler JJ, Fishman SJ, Kilroy SM et al. Increased expression of urinary matrix metalloproteinases parallels the extent and activity of vascular anomalies. Pediatrics; 2005;116(1): 38–45.
Kleinman ME, Greives MR, Churgin SS et al. Hypoxia-induced mediators of stem/progenitor cell trafficking are increased in children with hemangioma. Arterioscler Thromb Vasc Biol. 2007; 27(12): 2664–70.
Howard MA, Olitsky SE, Rychwalski P, Mungan N: Management of periocular infantile hemangioma. J Pediatr Ophthalmol Strabismus. 2019; 56:344–346.
Léauté-Labrèze C, Harper JI, Hoeger PH: Infantile haemangioma. Lancet.2017; 390:85–94.
Yuzuriha S, Nagai F, Noguchi M. How to manage disfiguring scars in involuted infantile hemangioma. Adv Wound Care (New Rochelle).2019; 8:221–229.
Chen ZY, Wang QN, Zhu YH, et al. Progress in the treatment of infantile hemangioma. Ann Transl Med. 2019 ;7(22):692.
Chinnadurai S, Sathe NA, Surawicz T. Laser treatment of infantile hemangioma: A
systematic review. Lasers Surg Med. 2016; 48:221–233.
Chai Y, Zhou Z, Song J, et al. Safety of intralesional injection of lauromacrogol combined with triamcinolone for infantile hemangiomas. J Dermatol. 2019; 46:770–776.
Sinha S, Lloyd MS: Propranolol for surgeons in the treatment of infantile hemangiomas. J Craniofac Surg. 2020; 31:134–137.
Qiu Y, Lin X, Ma G, et al. Eighteen cases of soft tissue atrophy after intralesional bleomycin a5 injections for the treatment of infantile hemangiomas: A long-term follow-up. Pediatr Dermatol.2015; 32:188–191.
Techasatian L, Phukam N. Treatment modalities and outcomes of infantile hemangiomas at srinagarind hospital. J Med Assoc Thai. 2016; 99 (Suppl 5): S74–S80.
White CW, Sondheimer HM, Crouch EC, et al. Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a. N Engl J Med.1989; 320:1197–1200.
Soliman YS, Khachemoune A. Infantile hemangiomas: Our current understanding and treatment options. Dermatol Online J.2018; 24(13030/qt5jt8q9km).
Greenberger S, Boscolo E, Adini I,et al . Corticosteroid suppression of VEGF-A in infantile hemangioma-derived stem cells. N Engl J Med. 2010; 18. 362(11):1005-13.
Town WG. The Merck index 13.2 CD-ROM edition from Cambridge Soft. J Chem Inf Comput Sci. 2004;44(5):1883–1885.
- Moisan F, Oucherif S, Kaulanjan-Checkmodine P, et al. Critical role of Aquaporin-1 and telocytes in infantile hemangioma response to propranolol beta blockade. Proc Natl Acad Sci U S A. 2021; 118:7.
Chim H, Armijo BS, Miller E, et al. Propranolol induces regression of hemangioma cells through HIF-1alpha-mediated inhibition of VEGF-A. Ann Surg. 2012;256 (1):146–156.
Tani S, Kunimoto K, Inaba Y, et al. Change of serum cytokine profiles by propranolol treatment in patients with infantile hemangioma. Drug Discov Ther. 2020;14(2):89–92.
Pandey A, Singh A, Ali W, et al. Evaluation of effect of propranolol on serum vascular endothelial growth factor and tissue inhibitor of metalloproteinase-2 levels in infantile hemangioma. J Indian Assoc Pediatr Surg. 2020;25(2):96–102.
Sharquie K E, Noaimi A A. Treatment of Kaposi’s Sarcoma by combination of zinc sulfateand propranolol. Journal of Cosmetics, Dermatological Sciences and Applications.2018; 8:249-255.
Sharquie KE, Jabbar RI. Triple therapy of Kaposi’s sarcoma using oral propranolol,oral zinc sulfate and oral acyclovir as new initiative study. Journal of Pakistan association of Dermatologists.2023;33(1):72-77.
Sharquie KE, Noaimi AA, Radhi SK. Burn hemangioma (scalded pyogenic granuloma) versus infantile hemangioma: Report of six cases of burn hemangioma and its effective therapy with oral propranolol. J Cosm Dermatol Scien Applicat. 2017; 7:229-44.
Sharquie KE, Al-Dhalimi MA, Kawen AA, Dhaher SA. Burn Hemangioma: A New Variant of Hemangioma. Dermatology. 2022;238(4):793-798.
Wine Lee L, Goff KL, Lam JM, et al. Treatment of pediatric pyogenic granulomas using ß-adrenergic receptor antagonists. Pediatr Dermatol.2014;31:203-7.
Craige H, Cohen JB. Symptomatic treatment of idiopathic and rosacea-associated cutaneous flushing with propranolol. J Am Acad Dermatol . 2005; 53:881-4.
McCourt C, Coleman HG, Murray LJ, et al. Beta-blocker usage after malignant melanoma diagnosis and survival: A population-based nested case-control study. Br J Dermatol 2014; 170:930-8.
Sharquie KE, Jabbar RI. Heat dermabrasion with needle diathermy combined with 35% TCA peeling as an innovative therapy for acne scarring in patients with a dark complexion. Our Dermatol Online. 2021;12(3):230-237.
Khan M, Boyce A, Prieto-Merino D,et al . The role of topical timolol in the treatment of infantile hemangiomas: a systematic review and meta-analysis. Acta Derm Venereol.
;97(10):1167-1171.
Ge J, Zheng J, Zhang L, et al. Oral propranolol combined with topical timolol for compound infantile hemangiomas: a retrospective study. Sci Rep. 2016; 28(6) :19765.
Tong S, Xu DP, Liu ZM, et al . Evaluation of the efficacy and safety of topical timolol maleate combined with oral propranolol treatment for parotid mixed infantile hemangiomas. Oncol Lett. 2016; 12(3):1806-1810.
Aly MM, Hamza AF, Abdel Kader HM,et al .Therapeutic superiority of combined
propranolol with short steroids course over propranolol monotherapy in infantile hemangioma. Eur J Pediatr. 2015 ;174(11):1503-9.
Heredea R E, Melnic E, Cirligeriu LE, et al. VEGF pathway gene expression profile of proliferating versus involuting infantile hemangiomas: Preliminary evidence and review of the literature. Children.2022;9: 908.
England RW, Hardy KL, Kitajewski AM, et al. Propranolol promotes
accelerated and dysregulated adipogenesis in hemangioma stem cells. Ann Plast Surg.2014;73: S119–24.
Price CJ, Lattouf C, Baum B, et al. Propranolol vs. corticosteroids for infantile hemangiomas: A multicenter retrospective analysis. Arch Dermatol. 2011; 147:1371-6.
Jalil S, Akhtar J, Ahmed S. Corticosteroids therapy in the management of infantile cutaneous hemangiomas. Journal of the College of Physicians and Surgeons— Pakistan: JCPSP. 2006;16(10):662–5.
Yu L, Li S, Su B, et al. Treatment of superficial infantile hemangiomas with timolol:
evaluation of short-term efficacy and safety in infants. Exp Ther Med. 2013; 6:388–90.
Wu HW, Wang X, Zhang L, et al. Topical timolol vs. oral propranolol for the treatment of superficial infantile hemangiomas. Front Oncol. 2018; 8:605.
Zhang L, Wu HW, Yuan W, Zheng JW. Propranolol therapy for infantile hemangioma: Our experience. Drug Des Devel Ther. 2017; 11:1401–1408.
Holland KE, Frieden IJ, Frommelt PC, et al. Hypoglycaemia in children taking propranolol for the treatment of infantile haemangioma. Arch Dermatol. 2010; 146(7):775-8
Zimmermann AP, Wiegand S, Werner JA, Eivazi, B. Propranolol therapy for infantile
haemangiomas: Review of the literature. Int J Ped Otorhinolaryngol. 2010; 74(4):338-42.
-Boon LM, MacDonald DM, Mulliken JB. Complications of systemic corticosteroid therapy for problematic hemangioma. Plast Reconstr Surg. 1999; 104:1616-23.
Rössler J, Wehl G, Niemeyer CM. Evaluating systemic prednisone therapy for proliferating haemangioma in infancy. Eur J Pediatr .2008; 167:813-5.
Malik MA, Menon P, Rao KL, Samujh R. Effect of propranolol vs prednisolone vs
propranolol with prednisolone in the management of infantile hemangioma: a randomized
controlled study. J Pediatr Surg. 2013 ;48(12):2453-9.
Lou Y, Peng WJ, Cao Y, et al. The effectiveness of propranolol in treating infantile
haemangiomas: A meta-analysis including 35 studies. Br. J. Clin. Pharmacol. 2014; 78: 44–57.
Witman PM, Wagner AM, Scherer K, et al. Complications following pulsed dye laser
treatment of superficial hemangiomas. Lasers Surg Med. 2006;38(2):116–123.
Batta K, Goodyear HM, Moss C, et al. Randomised controlled study of early pulsed dye laser treatment of uncomplicated childhood haemangiomas: results of a 1-year analysis. Lancet. 2002;360(9332):521–527.
Kessels JP, Hamers ET, Ostertag JU. Superficial hemangioma: pulsed dye laser versus wait-and-see. Dermatol Surg. 2013;39(3 Pt 1):414–421.
